Lilly says patients saw mean weight reduction of 58 lbs on retatrutide
LLY -1.33%Jun. 26, 2023 7:15 PM ET22 Comments
Eli Lilly (NYSE:LLY) said patients in a Phase 2 clinical trial for its drug retatrutide saw a mean weight reduction of up to roughly 58 pounds, or 24% of their body weight, after 48 weeks.
Lilly presented the data at a meeting of the American Diabetes Association on Monday. The data was simultaneously published in the New England Journal of Medicine.
The drugmaker said that the most commonly reported negative side-effects of the drug was mild-to-moderate gastrointestinal problems. It noted that patients did not appear to have plateaued in their weight loss by the end of the trial, indicating that they might continue to lose weight if they stayed on the drug.
Lilly is planning to initiate a Phase 3 study of the drug. The study will evaluate the safety and effectiveness of retatrutide in chronic weight management, sleep apnea and knee osteoarthritis in overweight and obese patients, Lilly said.
Retatrutide belongs to a class of drugs known as GLP-1 agonists, which includes Lilly's Mounjaro and Novo Nordisk's (NVO) Wegovy and Ozempic. The drugs were originally developed to treat diabetes but have been shown to be effective for weight loss.
Mounjaro, also known as tirzepatide, is currently in Phase 3 clinical trials for obesity. Lilly presented positive data on the drug at the ADA conference this past weekend.
Market Data 
Markets 
AI
